Rustem Gafanov
0000-0002-7592-0392
Publication & Citation Trends
Publications
0 total
Circulating tumor DNA (ctDNA) analysis in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC) treated with first-line pembrolizumab (pembro) monotherapy from the phase 2 KEYNOTE-427 study.
Cited by 0
Semantic Scholar
Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer.
Cited by 1
Semantic Scholar
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial
Cited by 21
Semantic Scholar
Research Topics
Renal cell carcinoma treatment
(43)
Cancer Immunotherapy and Biomarkers
(35)
Prostate Cancer Treatment and Research
(34)
Renal and related cancers
(19)
Bladder and Urothelial Cancer Treatments
(15)
Affiliations
Space Research Institute
Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology
Ministry of Health of the Russian Federation